| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 19,488 | 38,032 | ||
| Inventory | 18,418 | 11,067 | ||
| Accounts receivable | 1,078 | 394 | ||
| Prepaid expenses and other current assets | 2,367 | 2,237 | ||
| Total current assets | 41,351 | 51,730 | ||
| Restricted cash | 209 | 50,209 | ||
| Property and equipment, net | 19,857 | 21,191 | ||
| Finance lease right-of-use assets, net | 29,420 | 14,443 | ||
| Other long-term assets | 672 | 1,222 | ||
| Total assets | 91,509 | 138,795 | ||
| Accounts payable | 9,575 | 6,629 | ||
| Accrued expenses | 10,264 | 9,186 | ||
| Finance lease obligation, current portion | 2,670 | 3,093 | ||
| Revenue interest liability, current portion | 3,072 | 2,116 | ||
| Other current liabilities | 0 | 61 | ||
| Total current liabilities | 25,581 | 21,085 | ||
| Revenue interest liability, net of current portion | 17,674 | 66,425 | ||
| Contingent earnout liability | 21,807 | 26,700 | ||
| Finance lease obligation, net of current portion | 27,155 | 12,030 | ||
| Common stock warrant liabilities | 3,234 | 4,358 | ||
| Contingent derivative liability | 289 | 3,161 | ||
| Other long-term liabilities | 520 | 984 | ||
| Total liabilities | 96,260 | 134,743 | ||
| Common stock, 0.0001 par value 350,000,000 and 250,000,000 shares authorized as of september30, 2025 and december31, 2024, respectively 158,835,303 and 130,027,509 shares issued and outstanding as of september30, 2025 and december31, 2024, respectively | 16 | 16 | ||
| Additional paid-in capital | 697,277 | 688,570 | ||
| Accumulated deficit | -702,044 | -684,534 | ||
| Total stockholders equity (deficit) | -4,751 | 4,052 | ||
| Total liabilities and stockholders equity (deficit) | 91,509 | 138,795 | ||
Humacyte, Inc. (HUMAW)
Humacyte, Inc. (HUMAW)